Transcend Therapeutics Presents New Data from the Open-Label Portion of the IMPACT-1 Study and Further Data Supporting the Neuroplasticity Mechanism of TSND-201

TSND-201 (Methylone) for the Treatment of PTSD: Improvements across each CAPS-5 Cluster and Anxiety Symptoms from the Open-Label Portion of the IMPACT-1 Study

TSND-201 (Methylone): A Rapid-Acting Neuroplastogen that Stimulates Neurite Outgrowth

Fierce Biotech: Psychiatry biotech hopes to Transcend PTSD rivals with new data

TSND-201 (methylone) for PTSD: Initial Results from Open-Label Study (IMPACT-1)

Transcend Therapeutics Announces Positive Open-Label Data from IMPACT-1

Methylone: Distinct Pharmacological and Mechanistic Effects Compared with MDMA

Transcend and Yale awarded U.S. Department of Defense grant to study methylone for PTSD

Wall Street Backs New Class of Psychedelic Drugs

Our story: Letter from Blake Mandell, Co-founder and CEO, to Transcend Investors

Transcend Therapeutics announces Series A funding round of $40 million

Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity